Ultromics
PrivateLast Round
Corporate Funding
Dec 17, 2025
Est. Valuation
$300M
Total Funding Raised
$104M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ultromics operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Corporate Funding round in December 2025.
Ultromics is a health tech company that provides an AI-powered cardiovascular diagnostic platform, EchoGo, to analyze echocardiograms for the early and more accurate detection of heart disease.
Sector
Healthcare & Life Sciences
Verticals
Medical AI, Medical Imaging, Healthcare Analytics, Computer Vision
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ultromics Comparables
Compare Ultromics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Us2.ai | 86% | |
| Echo IQ Limited | 83% | |
| Ligence | 81% |
For institutional investors. Book with your work email.
Ultromics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Corporate Funding | Dec 17, 2025 | ||||
| Series C | Jul 31, 2025 | ||||
| Series B | Aug 16, 2021 | ||||
| Grant | Sep 8, 2020 | ||||
| VC Round | Jun 18, 2020 | ||||
Series A | May 23, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ultromics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UCM Ventures | Series C |
| Nina Capital | VC Round |
| GV | Series B, Series C |
| Legal & General Group | Series C |
| Oxford Science Enterprises | VC Round, Series B, Series C, Series A, Seed |
| NHSX | Grant |
| Tanarra | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors grew 84% MoM, reaching 19.2K.
- Feb 23, 2026
Achieved Category III CPT reimbursement from the Centers for Medicare & Medicaid Services.
For institutional investors. Book with your work email.
Ultromics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ultromics's valuation, stock price, and market status.
Is Ultromics a public or private company?
Ultromics is a private company.
What is the current stock price of Ultromics?
Ultromics is a private company, so its shares have no public market price. Caplight tracks Ultromics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ultromics worth (valuation)?
Ultromics's valuation is estimated at $300.0M based on funding round data.
Can I buy Ultromics stock?
Ultromics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ultromics's last funding round?
Ultromics's most recent funding round was Corporate Funding on December 17, 2025.
Who are the main investors in Ultromics?
Key investors in Ultromics include Legal & General Group, Oxford Science Enterprises, AllegisCyber, Allegis Capital, Lightrock.
Will Ultromics IPO soon?
No public IPO plans have been announced for Ultromics.
How can I track Ultromics secondary market activity?
Caplight tracks bids, offers, and trades in Ultromics's shares on secondary markets.